TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01388088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day
Study: NCT02040792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02723279
Drug: TT
Normalized name: TTL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
Study: NCT01890902
Drug: Ketoprofen 10% Cream
Normalized name: KETOPROFEN 10% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01890902
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03775278
Drug: PHP-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT02382406
Drug: MK-3475 (Phase I)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Study: NCT02382406
Drug: MK-3475 (Phase II)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years.
Study: NCT01446042
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal testosterone
Study: NCT02447380
Drug: AZD6094
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6094 600MG qd
Study: NCT02303639
Drug: Antiarrhythmic drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (or sotalol) for prevention of VT/VF relapses
Study: NCT02944526
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
Study: NCT02200029
Drug: Ademetionine IV+tablet
Normalized name: ademetionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
Study: NCT02200029
Drug: Ademetionine tablet
Normalized name: ademetionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
Study: NCT00776984
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
Study: NCT00661466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00274846
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -5 and -4: 60 mg/kg
Study: NCT03235037
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
Study: NCT01096160
Drug: MK-8226 BID, 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Study: NCT01096160
Drug: MK-8266 BID, 1.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Study: NCT01096160
Drug: MK-8266 TID, 1.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Study: NCT01096160
Drug: MK-8266 TID, 2.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Study: NCT01096160
Drug: MK-8266 TID, 2.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
Study: NCT01096160
Drug: Placebo BID (Panel A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
Study: NCT01096160
Drug: Placebo BID (Panel B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
Study: NCT01096160
Drug: Placebo TID (Panel C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
Study: NCT01096160
Drug: Placebo TID (Panel D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
Study: NCT01589380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
Study: NCT03331848
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT03331848
Drug: PXT002331 - 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04113941
Drug: Neuronox
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intradetrusor injection
Study: NCT04113941
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradetrusor injection
Study: NCT02091414
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per the practice of each participating center
Study: NCT04978688
Drug: E2/NETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as an oral tablet once daily.
Study: NCT02144038
Drug: LGH447
Approvals — FDA: no, EMA: no, PMDA: no
Description: pan-PIM inhibitor
Study: NCT02144038
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI3K-alpha inhibitor
Study: NCT01854372
Drug: R-HCVAD and R-MC
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01313299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.M. (in the muscle) injection on day 1 of a single treatment cycle.
Study: NCT04453761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NaCl0.9%
Study: NCT02849509
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist or Pradaxa
Study: NCT02465944
Drug: FFP104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
Study: NCT02465944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
Study: NCT01482871
Drug: ALG-1001
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT01482871
Drug: ALG-1001
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT01482871
Drug: ALG-1001
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT01482871
Drug: ALG-1001
Normalized name: DRESSING,BIATAIN ALG 2IN X 2IN C#3705
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT02186977
Drug: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
Study: NCT02186977
Drug: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
Study: NCT00537186
Drug: Iron oligosaccharide
Normalized name: chitosan oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00784719
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
Study: NCT00784719
Drug: CP-690,550 Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic topical solution, dosed at least once/day, 8 weeks
Study: NCT00908414
Drug: TMC589337 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
Study: NCT00908414
Drug: TMC589337 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
Study: NCT00908414
Drug: TMC589354 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
Study: NCT00908414
Drug: TMC589354 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
Study: NCT00908414
Drug: TMC589337 AA mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
Study: NCT00908414
Drug: TMC589337 EE mg
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
Study: NCT00908414
Drug: TMC310911 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive TMC310911 600 mg in Panel 7.
Study: NCT00908414
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
Study: NCT00023621
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01948921
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01628783
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT03138356
Drug: 2.5 mg ONGLYZA® (saxagliptin) tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used in treatments C and F.
Study: NCT03138356
Drug: 500 mg Glucophage XR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Used in treatments C, F and I.
Study: NCT02155985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for aspirin
Study: NCT02998151
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 20mg pills
Study: NCT02998151
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 135mg pills
Study: NCT02998151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: NCT01345812
Drug: HP-HMG
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 - 300 IU for stimulation of women in ART treatment
Study: NCT01345812
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 -300 IU for stimulation of women in ART treatment
Study: NCT02256813
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02188784
Drug: Polysaccharide Iron Complex 150 mg
Normalized name: polysaccharide iron complex 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iron
Study: NCT02188784
Drug: Placebo (for Polysaccharide Iron Complex)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar capsule designed to mimic Polysaccharide Iron Complex.
Study: NCT02070289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, BID, 14 days
Study: NCT02070289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, BID or titration, 14 days
Study: NCT00276016
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules
Study: NCT00005067
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo photodynamic therapy
Study: NCT01388933
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15g as 5g three times daily, orally for 8 consecutive weeks
Study: NCT01843699
Drug: Placebo matching tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00665106
Drug: NOVA63035 Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection in the study eye
Study: NCT00990821
Drug: 90 mg MK-0517 (PS80)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
Study: NCT00990821
Drug: 100 mg MK-0517 (PS80)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study: NCT00990821
Drug: 115 mg MK-0517 (PS80)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study: NCT00990821
Drug: 150 mg MK-0517 (PS80)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
Study: NCT00990821
Drug: 40 mg MK-0517 (non-PS80)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Study: NCT00990821
Drug: 100 mg MK-0517 (non-PS80)
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Study: NCT00990821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching MK-0517
Study: NCT02251821
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02251821
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01033097
Drug: DNK333 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral
Study: NCT01033097
Drug: Placebo to 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg placebo oral
Study: NCT01033097
Drug: DNK333 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral
Study: NCT01033097
Drug: Placebo to 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg placebo oral
Study: NCT01033097
Drug: DNK333 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral
Study: NCT01033097
Drug: Placebo to 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg placebo oral
Study: NCT01033097
Drug: DNK333 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral
Study: NCT01033097
Drug: Placebo to 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg placebo oral
Study: NCT04372186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.
Study: NCT02648282
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 21 days for a total of 8 doses. In the extended treatment phase, eligible patients may receive 200 mg/m2 as a 30 minute IV infusion one day prior to GVAX Pancreas Vaccine every 6 months for an additional 4 doses.
Study: NCT00946998
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet will be identical and matched to sertraline tablet.
Study: NCT02936492
Drug: BAY1003803 0.01% lipophilic cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration for 22 h per day
Study: NCT02936492
Drug: BAY1003803 0.1% lipophilic cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration for 22 h per day
Study: NCT02936492
Drug: BAY1003803 0.01% ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration for 22 h per day
Study: NCT02936492
Drug: BAY1003803 0.1% ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration for 22 h per day
Study: NCT04621058
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules exactly the same as the above, but without the active component.
Study: NCT02306213
Drug: Hydroxyethylstarch 6% 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
Study: NCT01314898
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg spironolactone, single oral dose
Study: NCT03698617
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
Study: NCT02983890
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned
Study: NCT02591914
Drug: Fovista™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PDGF-B pegylated aptamer
Study: NCT02591914
Drug: Lucentis®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-VEGF
Study: NCT02591914
Drug: Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-VEGF
Study: NCT02591914
Drug: Eylea®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-VEGF
Study: NCT00420563
Drug: CYCLOPHOSPHAMIDE
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
Study: NCT00282828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092313
Drug: MK0966, rofecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00092313
Drug: Comparator: oxycodone and acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04276636
Drug: Caltrate Pill
Normalized name: Caltrate Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
Study: NCT01779557
Drug: Huaren Peritoneal Dialysate
Normalized name: PERITONEAL DIALYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaren Peritoneal dialysate CAPD 3-5 times/d
Study: NCT01779557
Drug: Baxter Peritoneal Dialysate
Normalized name: PERITONEAL DIALYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxter Peritoneal dialysate CAPD 3-5 times/d
Study: NCT02312609
Drug: Minocycline hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: extended release tablets 135 mg
Study: NCT02733835
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
Study: NCT01602003
Drug: LC15-0444 25mg bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
Study: NCT02773407
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02773407
Drug: Co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01635621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
Study: NCT03087851
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous infusion of 5 mg zoledronic acid
Study: NCT02679079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00359684
Drug: Cysteamine
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cystine-depleting agent
Study: NCT01812707
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen
Study: NCT00002878
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01769352
Drug: PredA + Kelac
Approvals — FDA: no, EMA: no, PMDA: no
Description: At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
Study: NCT02339506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.